Childhood leukemia maintenance drug trial withdrawn before enrollment
NCT ID NCT07498465
First seen Apr 03, 2026 · Last updated May 13, 2026 · Updated 3 times
Summary
This trial was designed to test the safety and best dose of the drug revumenib in children with certain types of leukemia after they had a stem cell transplant. The goal was to see if revumenib could help keep the cancer from coming back. However, the study was withdrawn before any patients were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.